IXICO Stock

IXICO ROCE

The Return on Capital Employed (ROCE) of IXICO (IXI.L) as of Aug 10, 2026 is -21.76 %. In the previous year, Return on Capital Employed (ROCE) was -22.76 % — a change of -4.39% (higher).

ROCE

-21.76 %

YoY

-4.39%

Last updated:

In 2026, IXICO's return on capital employed (ROCE) was -21.76 %, a -4.39% increase from the -22.76 % ROCE in the previous year.

Access this data via the Eulerpool API

IXICO Stock analysis

What does IXICO do? IXICO PLC is a leading company in the field of digital biomarker and data services in clinical development. The company was originally founded in London in 2004 and has since had a successful history in neurology and psychiatry research. IXICO's core competency lies in developing and commercially implementing innovative solutions in the field of digital biomarker analysis, data capture, and processing. Through the use of advanced image analysis, structural analysis, and cognitive assessment technologies, IXICO enables effective clinical development of drugs and therapies, particularly in the areas of neurological and psychiatric disorders. IXICO is organized into three main divisions: Digital Healthcare Analytics (DHA), Data Analytics Services (DAS), and Clinical Trial Technology Solutions (CTTS). Each division includes its own products and services tailored to meet the specific requirements and needs of customers. The Digital Healthcare Analytics division focuses on developing biomarker-based clinical software-as-a-service (SaaS) solutions. These are used for monitoring and diagnosing neurological disorders such as Alzheimer's, Parkinson's, and schizophrenia. The solutions developed are tailored to the needs of clinics, research institutions, and biopharmaceutical companies and significantly contribute to the improvement of patient analysis and treatment. The Data Analytics Services division includes a wide range of services for data capture, processing, and analysis. This includes, for example, image and data analysis of clinical data, support for sponsors in data management and study monitoring, as well as consulting and training services. The purpose of this division is to help sponsors work in compliance with regulatory requirements and best practices in the pharmaceutical industry. IXICO's Clinical Trial Technology Solutions division offers a range of technology solutions to support the clinical research of pharmaceutical and biotechnology companies. This includes software solutions such as Neurostatus.net, a neurostatus toolkit for digital assessment of neurological patients, and TrialTracker, a SaaS solution that supports sponsors in the planning and conduct of studies. With its pioneering products and services, IXICO has numerous customers worldwide, including large pharmaceutical and biotech companies. The company also has partnerships with some of the most renowned academic institutions in Europe and North America and is proud to have been part of some of the most significant clinical studies in the field of neurology in recent years. Under the leadership of founder and CEO Derek Hill, IXICO has built an experienced and highly qualified team of scientists and industry experts over the years. The employees come from a variety of disciplines and industries and work closely together to develop innovative solutions and meet customer needs. The company expects to continue successfully focusing on the development of technology-based solutions in clinical research in the future. IXICO is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling IXICO's Return on Capital Employed (ROCE)

IXICO's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing IXICO's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

IXICO's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in IXICO’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about IXICO stock

Return on Capital Employed (ROCE) of IXICO is -21.76 % in 2026.

Return on Capital Employed (ROCE) of IXICO changed from -22.76 % to -21.76 %, representing a -4.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) IXICO since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s IXICO with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — IXICO

All Key Metrics — IXICO